The peptide-receptor radinuclide therapy with radiopharmaceutical 177Lu-DOTA-TATE.

Introduction: Since 2016, peptide-receptor radionuclide therapy (PRRT) with 177Lu-labeled somatostatin analogues has become a recognized treatment option in the second or third line of patients with progressive differentiated (grade G1–2) gastroentero pancreatic neuroendocrine tumors (GEP-NET) with radiopharmaceutical 177Lu-DOTA-TATE. Based on the results of the NETTER-II study, PRRT is being actively introduced as a first-line therapy for GEP-NETs, as a neoadjuvant treatment. Purpose: Analysis of the effectiveness and safety of the peptide-receptor radionuclide therapy method 177Lu-DOTA-TATE, according to world literature. Materials and methods: The search for literary sources was carried out in the period from 01.06.2024 to 12.12.2024 in the databases: Pubmed, Google Scholar, ELibrary using the search queries: 177Lu-DOTA-TATE, 177Lu and NET, peptid-receptor radionuclide therapy. Results: This method of radiotargeting therapy used to treat patients with metastatic and inoperable neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC) expressing type 2 somatostatin receptors (SSTR2) [1]. The increase in the incidence and prevalence of NET in recent decades [2], and the development of specific treatment methods and protocols, there is a growing use of this type of radiotargeted therapy 177Lu-DOTA-TATE. Discussion: 177Lu-DOTA-TATE approved by relevant foreign medical regulatory organizations: FDA, EMA [3, 4]. Analysis of the PRRT method, treatment results, and side effects characterizes this method of radionuclide therapy as safe and highly effective. Conclusion: The treatment of patients with NETs and NECs, including PRRT, requires a wide range of specialized clinical knowledge, which necessitates discussing patients in an expert multidisciplinary team of clinicians (oncologists, endocrinologists, chemotherapists, radiologists, radiotherapists, pathologists and other specialists).